Acura Pharmaceuticals (ACUR) Getting Somewhat Positive News Coverage, Report Finds
News articles about Acura Pharmaceuticals (NASDAQ:ACUR) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Acura Pharmaceuticals earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 45.6305077759243 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- ETFs with exposure to Acura Pharmaceuticals, Inc. : September 7, 2017 (finance.yahoo.com)
- Pain Management Therapeutics Market – Positive long-term growth outlook 2017 – 2025 – Medgadget (blog) (medgadget.com)
- Acura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 (finance.yahoo.com)
Shares of Acura Pharmaceuticals (ACUR) traded up 2.25% on Friday, hitting $0.44. 7,933 shares of the stock traded hands. Acura Pharmaceuticals has a one year low of $0.40 and a one year high of $1.87. The company’s market cap is $9.15 million. The stock has a 50 day moving average of $0.47 and a 200 day moving average of $0.52.
Acura Pharmaceuticals (NASDAQ:ACUR) last announced its quarterly earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.07. Acura Pharmaceuticals had a negative return on equity of 1,237.56% and a negative net margin of 2,335.87%. The firm had revenue of $0.09 million for the quarter. Equities analysts anticipate that Acura Pharmaceuticals will post ($0.46) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/08/acura-pharmaceuticals-acur-getting-somewhat-positive-news-coverage-report-finds.html.
Acura Pharmaceuticals Company Profile
Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.
Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.